Latest Information Update: 17 Jan 2008
At a glance
- Originator Bristol-Myers Squibb
- Class Antithrombotics
- Mechanism of Action Fibrinogen receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 04 Nov 1997 No-Development-Reported for Thrombosis in USA (Unknown route)
- 09 Jan 1995 Preclinical development for Thrombosis in USA (Unknown route)